TRIATHALONBIKE

Tuesday, August 16, 2005

Adherex lands Glaxo deal worth up to $220M

Durham biopharmaceutical company Adherex has signed a deal with GlaxoSmithKline in which the 2 companies could exchange drugs under development, an arrangement that is potentially worth as much as $220 mln for the startup. more...

http://www.triathalonbike.com/equipmenttriathalon
Originally Posted on 17/08/2005 02:53:32Content source: http://www.myHealthcareNews.com/r.aspx?a=237236&d=

0 Comments:

Post a Comment

<< Home